With the acquisition of Nuevolution and its world-class DNA-encoded library platform, Amgen has a team of experts adept at making and screening billions to trillions of compounds to find promising leads. The huge increase in screening power will fuel Amgen’s search for bi-specific small molecules that can leverage existing biology to eliminate tough drug targets.
More on Amgen:
www.amgen.com
Our new drug discovery platform can search through a million times more compounds than original screening technology. This improvement has come from the combination of DNA and advanced chemistry.
Amgen Research Copenhagen has helped to lead the way in this research where each chemical compound has its own DNA barcode. This technology is allowing Amgen to attack targets previously thought undruggable.
20 ноя 2019
